What The Study Did: In this phase 1 study, a single immunization with Ad26.COV2.S (Janssen/Johnson & Johnson) vaccine induced rapid binding and neutralization antibody responses as well as cellular immune responses. Two phase 3 clinical trials are currently underway to determine the efficacy of the Ad26.COV2.S vaccine.
Authors: Dan H. Barouch, M.D., Ph.D., of Beth Israel Deaconess Medical Center in Boston, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https:/
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Media advisory: The full article is linked to this news release.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https:/
JAMA Network Media Relations